LOGIN  |  REGISTER
Viking Therapeutics
Assertio

Premier to Report Fiscal 2025 Fourth-Quarter and Full-Year Results and Host Conference Call on August 19, 2025

July 29, 2025 | Last Trade: US$28.26 0.00 0.00

CHARLOTTE, N.C. / Jul 29, 2025 / Business Wire / Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2025 fourth quarter and full year on Tuesday, August 19, 2025, at approximately 6:30 a.m. ET. The company will also host a conference call at 8:00 a.m. ET to discuss its financial results.

The live webcast and replay will be available in the Investors section of the company’s website at Events & Presentations. The webcast should be accessed 10 minutes prior to the conference call start time. The replay of the event will be available for one year following the conclusion of the live broadcast.

For those parties who do not have internet access, the conference call can be accessed by calling one of the below telephone numbers and asking to join the Premier, Inc. call:

Domestic participant dial-in number (toll-free):

 

(833) 953-2438

International participant dial-in number:

 

(412) 317-5767

About Premier, Inc.

Premier, Inc. (NASDAQ: PINC) is a leading technology-driven healthcare improvement company, providing solutions to two-thirds of all healthcare providers in the U.S. Playing a critical role in the rapidly evolving healthcare industry, Premier unites providers, suppliers, payers and policymakers to make healthcare better with national scale, smarter with actionable intelligence and faster with novel technologies. Headquartered in Charlotte, N.C., Premier offers integrated data and analytics, collaboratives, supply chain solutions, consulting and other services in service of our mission to improve the health of communities. Please visit Premier’s news and investor sites on www.premierinc.com, as well as X, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page